← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 11.6% to $297.2M, while Net income decreased 2.4% to ($51.6M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $297.2MWatch
- Profitability — Net income ($51.6M)Watch
- Cash generation — Free cash flow ($45.7M)Note
- Accounting — Formula distress score · no manipulation flag · earnings quality greyWatch
- Insiders — 1 buys; 7 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Business
Evolus, Inc.: our business, financial condition, results of operations and prospects, economic conditions, our plans and expectations regarding regulatory approvals and commercial launch of our products, the addressable market of our products, our industry and the regulatory environment in which we operate.
Where the revenue comes from
Fiscal 2025, as Evolus, Inc. reports it. History and quarterly detail are in the app.
- Product revenue, net$295.0M
- Service revenue$2.2M
Leadership changes
From Evolus, Inc.'s own filings, the day they're filed.
- Tatjana Mitchell · Chief Financial Officer · appointmenteff. 2025-09-08
- Sandra Beaver · Chief Financial Officer · departureeff. 2025-06-13
- Albert White III · departureeff. 2025-06-05
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-07-08
- 8-K · Company announcement2026-06-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Evolus, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.